Prot#AG10-304: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Project: Research project

Project Details

StatusActive
Effective start/end date12/1/21 → 12/1/27

Funding

  • Pharmaceutical Research Associates, Inc. (Prot#AG10-304 // Prot#AG10-304)
  • Eidos Therapeutics, Inc. (Prot#AG10-304 // Prot#AG10-304)